SQLite Web: event_store.db

Update row 39386 in events

seq

Primary key. INTEGER

id

TEXT NOT NULL

kind

TEXT NOT NULL

ts

TEXT NOT NULL

actor

TEXT

subject_entity_ids

TEXT

payload

{"created_at":"2026-04-14T02:04:49.876253+00:00","dedupe_key":"signal_enriched:discovery_sec_filing_delta:c94a179e838b1da4","evidence_event_ids":["evt_09ca1baf7c74"],"signal_type":"discovery_sec_filing_delta","source":"discovery_sec_filings","value":{"aggregator_url":"https://www.sec.gov/Archives/edgar/data/1453593/0001493152-26-016308.txt","as_of":"2026-04-14T02:04:49.876253+00:00","canonical_url":"https://www.sec.gov/Archives/edgar/data/1453593/0001493152-26-016308.txt","company":"Xtant Medical Holdings, Inc.","enrichment":{"aggregator_url":"https://www.sec.gov/Archives/edgar/data/1453593/0001493152-26-016308.txt","article_chars":5000,"article_truncated":true,"blocked_reason":null,"candidate_id":"sc_553b8455285a0623","canonical_host":"sec.gov","canonical_is_aggregator":false,"canonical_url":"https://www.sec.gov/Archives/edgar/data/1453593/0001493152-26-016308.txt","content_type":"text/plain","enriched_at":"2026-04-14T02:08:09.394540+00:00","extraction_method":"trafilatura","fetched_description":"","fetched_title":"","final_url":"https://www.sec.gov/Archives/edgar/data/1453593/0001493152-26-016308.txt","html_truncated":true,"paywall_likely":false,"publisher_domain":"sec.gov","publisher_resolution":"canonical_url","requested_url":"https://www.sec.gov/Archives/edgar/data/1453593/0001493152-26-016308.txt","source_event_id":"evt_09ca1baf7c74","source_quality":"high","status_code":200,"version":"signal_enrichment_v2"},"form_type":"8-K","fp":"0c5f147762957f7d","kind":"sec_filing","published_at":"20260413","publisher_domain":"sec.gov","signal_understanding":{"analysis_basis":"article","claim_confidence":0.78,"dates_mentioned":["2026-04-10","2026-04-13","2026-04-14"],"entities":[{"asset_class":"equity","name":"Xtant Medical Holdings, Inc.","relevance":"high","symbol":"XTNT","type":"issuer"},{"asset_class":"company","name":"Dilon Technologies, Inc.","relevance":"high","symbol":"","type":"counterparty"},{"asset_class":"medical_device_product","name":"HEMOBLAST\u00ae Bellows","relevance":"high","symbol":"","type":"product"}],"event_type":"listing","information_gaps":["The excerpt does not specify the exact Form 8-K Item number(s) beyond stating Item 7.01.","Termination \u201cspecified events\u201d and the \u201ccertain circumstances\u201d under which the $5.0 million exclusivity fee is repayable are not detailed in the provided text.","The excerpt does not provide the specified transfer price or how it changes under the agreement.","The excerpt does not include the complete press release text (it is truncated after the CEO quote).","No prior known state is provided in the prompt, so the specific \u201cwhat changed vs prior known state\u201d cannot be determined from the provided text alone."],"key_facts":["Form type: Current Report on Form 8-K.","Date of report/earliest event reported: April 13, 2026 (as stated in the filing text).","Xtant announced it entered into a Distribution Agreement with Dilon on April 10, 2026.","Under the Distribution Agreement, Xtant obtained exclusive rights to import, market, distribute, and sell HEMOBLAST\u00ae Bellows in the United States.","HEMOBLAST\u00ae Bellows is described as an FDA-approved powder-based, topical, surgical hemostatic agent used to control bleeding during surgical procedures.","Xtant is furnishing the information in Exhibit 99.1 pursuant to Regulation FD and Item 7.01 of Form 8-K.","Dilon will continue to manufacture the product from its current manufacturing location in France and supply/sell the product to Xtant at a specified transfer price subject to change under the agreement.","The Distribution Agreement does not contain any minimum purchase requirements on behalf of Xtant.","Xtant paid Dilon a $5.0 million exclusivity fee, subject to repayment by Dilon under certain circumstances, including upon termination of the Distribution Agreement.","Either party may terminate the Distribution Agreement upon certain specified events (details not provided in the excerpt).","Dilon agreed to cooperate to transition the existing U.S. customer base for the product to Xtant and assign existing customer contracts to Xtant, subject to Xtant\u2019s review and approval.","In connection with entering into the Distribution Agreement, Xtant hired approximately 20 Dilon sales personnel to assist in selling the product in the United States.","The full text of the press release is furnished as Exhibit 99.1 to the 8-K."],"numeric_claims":[{"label":"Exclusivity fee (USD)","value":"5.0 million"},{"label":"Sales personnel hired (approx.)","value":"20"},{"label":"Global addressable market (USD, estimated)","value":"2.0 billion"}],"primary_claim":"On April 13, 2026, Xtant filed an 8-K stating it entered into a Distribution Agreement with Dilon granting Xtant exclusive rights to import, market, distribute, and sell HEMOBLAST\u00ae Bellows in the United States.","relevance_score":0.62,"sentiment":"neutral","source_quality":"high","summary":"Xtant Medical Holdings, Inc. filed an 8-K announcing it entered into an exclusive U.S. Distribution Agreement with Dilon Technologies for the FDA-approved HEMOBLAST\u00ae Bellows hemostatic product. The filing discloses the agreement\u2019s key commercial terms, including an exclusivity fee and sales/customer transition arrangements.","topics":["SEC filing","8-K","distribution agreement","exclusive distribution rights","FDA-approved hemostatic agent","Regulation FD","exclusivity fee","customer transition"]},"source":"sec_edgar","source_domain":"sec.gov","summary":"Form 8-K \u00b7 Xtant Medical Holdings, Inc. \u00b7 Filed 20260413","ticker":"XTNT","tickers":["XTNT"],"title":"XTNT filed 8-K","url":"https://www.sec.gov/Archives/edgar/data/1453593/0001493152-26-016308.txt"}}

TEXT NOT NULL

source_ref

TEXT

confidence

REAL (default 0.0

dedupe_key

TEXT

episode_id

TEXT

created_at

TEXT NOT NULL (default strftime('%Y-%m-%dT%H:%M:%fZ','now')

Cancel